Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Aripiprazole in Patients With a History of Bipolar Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00036348
Recruitment Status : Completed
First Posted : May 10, 2002
Last Update Posted : November 11, 2013
Sponsor:
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary:
The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with a history of bipolar disorder.

Condition or disease Intervention/treatment Phase
Bipolar Disorder Drug: Aripiprazole Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Study Start Date : March 2000
Actual Primary Completion Date : June 2003
Actual Study Completion Date : June 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bipolar Disorder





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Patients with a history of Bipolar I Disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00036348


Locations
Layout table for location information
United States, Alabama
Local Institution
Birmingham, Alabama, United States
Local Institution
Tuscaloosa, Alabama, United States
United States, California
Local Institution
Chillicothe, California, United States
Local Institution
Riverside, California, United States
Local Institution
Stanford, California, United States
Local Institution
Torrance, California, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
United States, Illinois
Local Institution
Chicago, Illinois, United States
United States, Kentucky
Local Institution
Louisville, Kentucky, United States
United States, Louisiana
Local Institution
Shreveport, Louisiana, United States
United States, Massachusetts
Local Institution
Belmont, Massachusetts, United States
United States, Nevada
Local Institution
Las Vegas, Nevada, United States
United States, New Mexico
Local Institution
Albuquerque, New Mexico, United States
United States, New York
Local Institution
New York, New York, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
United States, Tennessee
Local Institution
Memphis, Tennessee, United States
Local Institution
Nashville, Tennessee, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
San Antonio, Texas, United States
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00036348    
Other Study ID Numbers: CN138-010
First Posted: May 10, 2002    Key Record Dates
Last Update Posted: November 11, 2013
Last Verified: September 2007
Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Bipolar I disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Aripiprazole
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Dopamine D2 Receptor Antagonists
Dopamine Antagonists